RETRACTION

We write to retract our report "Severe dopaminergic neurotoxicity in
primates after a common recreational dose regimen of MDMA ("ecstasy")"
(1), following our recent discovery that the drug used to treat all
but one animal in that report came from a bottle that contained
(+)-methamphetamine instead of the intended drug, ( )MDMA. Notably,
(+)-methamphetamine would be expected to produce the same pattern of
combined dopaminergic/serotonergic neurotoxicity (2) as that seen in
the animals reported in our paper (1).

The originally published report (1) presented results from multiple
studies performed in our laboratory over a span of approximately 2
years demonstrating that a novel systemic dose regimen of what we
believed was MDMA produced severe dopamine neurotoxicity in two
species of nonhuman primates, in addition to the previously reported
serotonin neurotoxicity (3-6). Subsequent to the publication of those
findings, we were unable to extend the dopamine neurotoxicity to
orally administered doses.

Multiple subsequent attempts to reproduce the original findings with
systemically administered doses of MDMA identical to those used in the
original study were also unsuccessful, under a variety of laboratory
conditions.

We then noted that our studies aimed at extending and replicating the
finding of MDMA-induced dopamine neurotoxicity were performed using a
new batch of MDMA. This new batch of MDMA was determined to be
authentic by several methods, including gas chromatography/ mass
spectrometry (GC/MS).

Upon investigation of our laboratory records, we determined that the
studies detailed in our paper (1) utilized a batch of MDMA that had
been requested on the same date as a batch of (+)-methamphetamine and
that both drug requests were for the same amount (10 g) and were
processed by the supplier on the same day. Both drugs were delivered
to our laboratory on the same day, in the same package.

At delivery, the two bottles had different affixed labels, the same
delivery reference number, but different batch numbers, as specified
in their respective chemical data sheets. Following receipt, both
drugs were stored in our laboratory in their original containers, in a
locked safe.

When we began to suspect that the two bottles of drug might have borne
incorrect labels [i.e., that the putative ( )MDMA was actually
(+)-methamphetamine, and vice versa], we requested that a sample of
the drug in the bottle bearing the original and intact label of
"(+)-methamphetamine HCl" be analyzed by various analytical
techniques, including GC/MS. Three independent laboratories found the
sample to consist of MDMA, with no evidence of even trace amounts of
methamphetamine.

Although the drug sample used in our original studies (1) was depleted
and the empty bottle labeled MDMA had been discarded, we did have
frozen brains from two animals that died shortly after drug treatment
during the course of the original experiments (1). When these brains
were analyzed by GC/MS by three independent laboratories, they were
found to contain methamphetamine and its metabolite amphetamine,
neither of which is a metabolite of MDMA (7). Not even trace amounts
of MDMA or its metabolite MDA were found in these brains.

Detailed review of our laboratory records revealed that all but one
animal in our study (1) had been treated with the drug in the bottle
labeled "( )-methylenedioxymethamphetamine HCl" (MDMA) processed on
the same date as the bottle labeled "(+)d-methamphetamine HCl."

This apparent labeling error does not call into question the results
of multiple previous studies demonstrating the serotonin neurotoxic
potential of MDMA in various animal species, including several
nonhuman primate species (3-6, 8). Regarding the dopamine neurotoxic
potential of MDMA in nonhuman primates, it remains possible that dose
regimens in the range of those used by some humans, but different from
those thus far tested, produce dopamine neurotoxicity in primates, as
they do in rodents (9, 10). Moreover, lasting effects of MDMA on
dopaminergic function in humans have recently been reported (11), and
some humans with a history of MDMA abuse have developed Parkinsonism
(12-14). However, until the dopamine neurotoxic potential of MDMA in
primates can be examined more fully, this possibility remains uncertain.

George A. Ricaurte, Department of Neurology, Johns Hopkins Bayview
Medical Center, Johns Hopkins University School of Medicine,
Baltimore, MD 21224, USA.

Jie Yuan, Department of Neurology, Johns Hopkins Bayview Medical
Center, Johns Hopkins University School of Medicine, Baltimore, MD
21224, USA.

George Hatzidimitriou, Department of Neurology, Johns Hopkins Bayview
Medical Center, Johns Hopkins University School of Medicine,
Baltimore, MD 21224, USA.

Branden J. Cord, Department of Neurosciences, Johns Hopkins Bayview
Medical Center, Johns Hopkins University School of Medicine,
Baltimore, MD 21224, USA.

Una D. McCann, Department of Psychiatry, Johns Hopkins Bayview Medical
Center, Johns Hopkins University School of Medicine, Baltimore, MD
21224, USA.

References and Notes

(1) G. A. Ricaurte, J. Yuan, G. Hatzidimitriou, B. J. Cord, U. D. McCann,
Science 297, 2260 (2002).

(2) V. Villemagne et al., J. Neurosci. 18, 419 (1998).

(3) G. A. Ricaurte, L. E. Delanney, I. Irwin, J. W. Langston, Brain Res.
446, 165 (1988).

(4) T. R. Insel, G. Battaglia, J. N. Johannessen, S. Marra, E. B. DeSouza,
J. Pharmacol. Exp. Ther. 249, 713 (1989).

(5) M. S. Kleven, W. L. Woolverton, L. S. Seiden, Brain Res. 488, 121 (1989).

(6) D. L. Frederick et al., Neurotoxicol. Teratol. 17, 531 (1995).

(7) A. Cho, Y. Kumagai, in Amphetamine and its Analogs:
Neuropsychopharmacology, Toxicology and Abuse, A. Cho, D. Segal, Eds.
(Academic Press, New York, 1994), pp. 43-77.

(8) W. Slikker Jr. et al., Toxicol. Appl. Pharmacol. 94, 448 (1988).

(9) D. L. Commins et al., J. Pharmacol. Exp. Ther. 241, 338 (1987).

(10) E. O'Shea, B. Esteban, J. Camarero, A. R. Green, M. I. Colado,
Neuropharmacology 40, 65 (2001).

(11) G. Gerra et al., Behav. Brain Res. 134, 403 (2002).

(12) S. Mintzer, S. Hickenbottom, S. Gilman, N. Engl. J. Med. 340, 1443
(1999).

(13) S. M. Kuniyoshi, J. Jankovic, N. Engl. J. Med. 349, 96 (2003).

(14) G. Ricaurte, unpublished data.

(15) We gratefully acknowledge helpful discussions with J. Katz, W. L.
Hearn, and N. Ator. We are also grateful for the expert chemical analytical
assistance of R. Fernandez, T. L. DalCason, M. Courtney, M. Daggett, I.
Carroll and associates, and R. Foltz.